Prospective, multicenter, spontaneous, non-interventional, non pharmacological. Study aimed at evaluate kinetics, diagnostic and prognostic value of pro-ADM (proadrenomedullin) as compared to PCT (procalcitonin) in patients presenting with infections or other complications post hematopoietic stem cell transplantation (HSCT)
Evaluation of diagnostic performance of pro-ADM as compared to palliative care therapy (PCT) in paediatric and young adult patients with any type of complications after hematopoietic stem cell transplantation or with transplant related complications.
Study Type
OBSERVATIONAL
Enrollment
200
observation and prospective data collection
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Turin, Italy
RECRUITINGEvaluation of diagnostic performance of pro-ADM as compared to PCT in patients receiving HSCT
In order to achieve the objective, it will be considered paediatric and young adults patients affected by malignant/non-malignant disorders who have been subjected to HSCT and present with infectious complications post HSCT or with transplant related complications (acute graft-versus-host disease (GvHD), sinusoidal obstruction syndrome (SOS), engraftment (ES) and pre-engraftment syndrome (pre-E), graft failure, thrombotic microangiopathy associated with HSCT (TA-TMA) or those without complications post HSCT).
Time frame: 180 days after HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.